MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

NCT00180401 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-02-23

No results posted yet for this study

Summary

The purpose of this study is to compare the benefit of cardiac resynchronization therapy (CRT)-therapy in patients with a QRS-complex of 120-150 ms to patients with a QRS-complex of \> 150 ms.

Conditions

Interventions

BEHAVIORAL

CRT-P and CRT-D devices

Sponsors & Collaborators

  • Guidant Corporation

    collaborator INDUSTRY
  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Andreas Tiroke, MD · Klinikum der Christian Albrecht Universität / Kardiologische Abteilung / Arnold Heller-Str. 7 / 24105 Kiel / Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2007-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180401 on ClinicalTrials.gov